MA56208A - Composés pyrazole disubstitués utilisés en tant qu'inhibiteurs de cétohexokinase - Google Patents

Composés pyrazole disubstitués utilisés en tant qu'inhibiteurs de cétohexokinase

Info

Publication number
MA56208A
MA56208A MA056208A MA56208A MA56208A MA 56208 A MA56208 A MA 56208A MA 056208 A MA056208 A MA 056208A MA 56208 A MA56208 A MA 56208A MA 56208 A MA56208 A MA 56208A
Authority
MA
Morocco
Prior art keywords
pyrazole
compounds used
disubstituted compounds
ketohexokinase inhibitors
ketohexokinase
Prior art date
Application number
MA056208A
Other languages
English (en)
Inventor
David Andrew Coates
Timothy Barrett Durham
Richard Duane Johnston
Steven Marc Massey
Patrick Gianpietro Spinazze
Douglas Richard Stack
James Lee Toth
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MA56208A publication Critical patent/MA56208A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
MA056208A 2019-06-17 2020-06-16 Composés pyrazole disubstitués utilisés en tant qu'inhibiteurs de cétohexokinase MA56208A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962862382P 2019-06-17 2019-06-17
US202062975887P 2020-02-13 2020-02-13

Publications (1)

Publication Number Publication Date
MA56208A true MA56208A (fr) 2022-04-20

Family

ID=71950812

Family Applications (1)

Application Number Title Priority Date Filing Date
MA056208A MA56208A (fr) 2019-06-17 2020-06-16 Composés pyrazole disubstitués utilisés en tant qu'inhibiteurs de cétohexokinase

Country Status (23)

Country Link
US (2) US11124500B2 (fr)
EP (1) EP3983404B1 (fr)
JP (2) JP6986653B2 (fr)
KR (1) KR20220008882A (fr)
CN (1) CN114008036B (fr)
AU (1) AU2020295979A1 (fr)
BR (1) BR112021023153A2 (fr)
CA (1) CA3143490C (fr)
CL (1) CL2021003342A1 (fr)
CO (1) CO2021016870A2 (fr)
CR (1) CR20210600A (fr)
EC (1) ECSP21091203A (fr)
ES (1) ES2961283T3 (fr)
IL (1) IL288350A (fr)
JO (1) JOP20210329A1 (fr)
MA (1) MA56208A (fr)
MX (1) MX2021015325A (fr)
PE (1) PE20220377A1 (fr)
PH (1) PH12021553161A1 (fr)
TW (1) TWI750685B (fr)
UA (1) UA126847C2 (fr)
WO (1) WO2020257171A1 (fr)
ZA (1) ZA202109067B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021129817A1 (fr) * 2019-12-25 2021-07-01 南京明德新药研发有限公司 Composé à base de pyrimidine ayant un effet inhibiteur de la cétohexokinase (chk)
CN114181198B (zh) * 2020-09-15 2025-07-15 山东轩竹医药科技有限公司 嘧啶衍生物类己酮糖激酶抑制剂及其用途
EP4269404A4 (fr) * 2020-12-25 2024-12-04 Xizang Haisco Pharmaceutical Co., Ltd. Inhibiteur de cétohexokinase et son utilisation
EP4313967B1 (fr) 2021-03-29 2025-11-12 Gilead Sciences, Inc. Inhibiteurs de khk
TWI833193B (zh) * 2021-04-01 2024-02-21 南韓商Ｌｇ化學股份有限公司 二唑化合物及含彼的藥學組成物
EP4434982A4 (fr) * 2021-12-24 2025-03-12 LG Chem, Ltd. Dérivé de (s)-2-(2-méthylazétidin-1-yl)pyrimidine et composition pharmaceutique le comprenant
AR132416A1 (es) * 2023-04-12 2025-06-25 Centennial Therapeutics Llc Compuestos de pirimidina disustituidos para la inhibición de la cetohexoquinasa
KR20260022334A (ko) 2023-05-31 2026-02-19 센테니얼 테라퓨틱스, 엘엘씨 케토헥소키나제 억제를 위한 이환식 화합물

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101111247B1 (ko) * 2009-07-17 2012-06-12 한국과학기술연구원 Ｒｏｓ 카이네이즈 저해활성을 갖는 피라졸 화합물
WO2017075367A1 (fr) * 2015-10-28 2017-05-04 Northwestern University Composés n-hétérocycliques aromatiques substitués en tant qu'inhibiteurs de protéine kinase activée par mitogène interagissant avec la kinase 1 (mnk1) et la kinase 2 (mnk2)
TN2018000198A1 (en) * 2015-12-29 2019-10-04 Pfizer Substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors
TWI714231B (zh) * 2018-09-04 2020-12-21 美商美國禮來大藥廠 2,6-二胺基吡啶化合物

Also Published As

Publication number Publication date
TW202112768A (zh) 2021-04-01
US11124500B2 (en) 2021-09-21
JP7221367B2 (ja) 2023-02-13
ECSP21091203A (es) 2022-01-31
US20220017496A1 (en) 2022-01-20
MX2021015325A (es) 2022-01-18
TWI750685B (zh) 2021-12-21
CA3143490C (fr) 2024-03-05
EP3983404A1 (fr) 2022-04-20
US20200392118A1 (en) 2020-12-17
JOP20210329A1 (ar) 2023-01-30
CR20210600A (es) 2022-01-11
KR20220008882A (ko) 2022-01-21
CL2021003342A1 (es) 2022-09-09
PE20220377A1 (es) 2022-03-16
ES2961283T3 (es) 2024-03-11
CA3143490A1 (fr) 2020-12-24
CN114008036A (zh) 2022-02-01
EP3983404B1 (fr) 2023-08-09
IL288350A (en) 2022-01-01
WO2020257171A1 (fr) 2020-12-24
JP6986653B2 (ja) 2021-12-22
ZA202109067B (en) 2023-06-28
CN114008036B (zh) 2025-01-17
JP2022031816A (ja) 2022-02-22
BR112021023153A2 (pt) 2022-01-04
JP2021525793A (ja) 2021-09-27
US11999722B2 (en) 2024-06-04
PH12021553161A1 (en) 2022-08-08
AU2020295979A1 (en) 2021-12-09
CO2021016870A2 (es) 2022-01-17
UA126847C2 (uk) 2023-02-08

Similar Documents

Publication Publication Date Title
MA56208A (fr) Composés pyrazole disubstitués utilisés en tant qu'inhibiteurs de cétohexokinase
EP3768661A4 (fr) Composés deutérés utilisés en tant qu'inhibiteurs de rock
MA56398A (fr) Composés 2,3-dihydroquinazoline en tant qu'inhibiteurs de nav1.8
MA51610A (fr) Dérivés d'imidazole fusionnés utilisés en tant qu'inhibiteurs d'il-17
MA54076A (fr) 2-amino-n-hétéroaryl-nicotinamides utilisés en tant qu'inhibiteurs de nav1.8
MA52486A (fr) Pyridazinones utilisés en tant qu'inhibiteurs de parp7
EP3873468A4 (fr) 2-amino-n-phényl-nicotinamides utilisés en tant qu'inhibiteurs de nav1.8
MA54169A (fr) Tolyles substitués utilisés en tant que fongicides
MA51846A (fr) Composés hétérocycliques utilisés en tant qu'inhibiteurs de kinases
MA52189A (fr) Benzothiophènes et composés associés utilisés en tant qu'agonistes de sting
MA51438A (fr) Composés hétérocycliques utilisés en tant qu'inhibiteurs de lsd1
MA49888A (fr) Composés macrocycliques utilisés en tant qu'inhibiteurs de kinase ros1
MA53220A (fr) Nouveaux composés hétérocycliques utilisés en tant qu'inhibiteurs de monoacylglycérol lipase
MA49374A (fr) Composés hétéroaromatiques utilisés en tant qu'inhibiteurs de vanine
MA54378A (fr) Composés hétéroaromatiques utilisés en tant qu'inhibiteurs de vanine
MA43169A (fr) Composés hétérocycliques utilisés en tant qu'inhibiteurs de pi3k-gamma
MA47013A (fr) Composés benzolactames utilisés en tant qu'inhibiteurs de protéine kinase
MA51429A (fr) Dérivés amino-fluoropipéridines utilisés en tant qu'inhibiteur de kinase
EP3733673A4 (fr) Dérivés d'oxy-fluoropipéridine utilisés en tant qu'inhibiteur de kinase
MA51327A (fr) Composés cycliques fusionnés en 5,5 à substitution diaryle, utilisés en tant qu'inhibiteurs du c5ar
MA42919A (fr) Composés bicycliques utilisés en tant qu'inhibiteurs d'atx
MA45375A (fr) Composés hétérocycliques utilisés en tant qu'agents antibacteriens
MA42918A (fr) Composés bicycliques utilisés en tant qu'inhibiteurs d'atx
EP3952865A4 (fr) Composés hétérocycliques en tant qu'inhibiteurs de kinase pour des utilisations thérapeutiques
MA49956A (fr) Composés de pyrimidine utilisés en tant qu'inhibiteurs de kinase jak